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STUDY PROTOCOL Open Access
Stop Antibiotics on guidance of Procalcitonin
Study (SAPS): a randomised prospective
multicenter investigator-initiated trial to analyse
whether daily measurements of procalcitonin
versus a standard-of-care approach can safely
shorten antibiotic duration in intensive care unit
patients - calculated sample size: 1816 patients
Evelien Assink-de Jong1, Dylan W de Lange2, Jos A van Oers3, Maarten W Nijsten4, Jos W Twisk5
and Albertus Beishuizen1,6*
Abstract
Background: Unnecessary long-term use of broad-spectrum antibiotics is linked to the emergence and selection of
resistant bacteria, prolonged hospitalisation and increased costs. Several clinical trials indicate that the biomarker
procalcitonin (PCT) can guide antibiotic therapy. Some of these trials have shown a promising reduction in the
number of antibiotic prescriptions, duration of antibiotic therapy and even length of stay in the ICU, although their
size and selection criteria limit their external validity. The objectives of the Stop Antibiotics on guidance of
Procalcitonin Study (SAPS) are to evaluate whether daily PCT can improve “real-life” antibiotic use in Dutch ICU’s by
reduction of the duration of antibiotic treatment without an increase of recurrent infections and mortality.
Methods/Design: Multicenter randomised controlled intervention trial. Powered for superiority of the primary
efficacy endpoint and non-inferiority on the primary safety endpoints (non-inferiority margin is set on 8%).
Inclusion criteria: (1) ICU-patients aged ≥18 years and (2) receiving antibiotics for a presumed or proven infection
and (3) signed informed consent. Exclusion criteria: (1) patients who require prolonged antibiotic therapy, (2) suffer
from Mycobacterium tuberculosis, (3) cystic fibrosis, (4) viral or parasitic infections and (5) those that are severely
immunocompromised or (6) moribund.
The intervention consists solely of an advice to discontinue antibiotic treatment in case PCT has decreased by more
than 80% of its peak level (relative stopping threshold) or decrease below a value of 0.5 ng/ml (absolute stopping
threshold).
The study hypothesis is that PCT-guided therapy is non-inferior to standard care based on implemented guidelines
and local expertise, whilst reducing antibiotic usage. Computerised 1:1 randomisation will allocate 908 patients per
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arm. Arm 1: standard of care. Arm 2: procalcitonin-guided therapy. The primary efficacy endpoint is consumption of
antibiotics expressed as the defined daily dosage and duration of antibiotic therapy expressed in days of therapy.
This trial is designed to shorten antibiotics safely, therefore the primary safety endpoint is mortality measured at
28 day and 1 year.
Discussion: This will be the largest procalcitonin-guided antibiotic intervention trial in ICU setting thus far.
Currently 1600 of the planned 1816 patients are randomised (November 2012). The first interim analysis has passed
without any safety or futility issues.
Trial registration: Trial registration number at www.clinicaltrials.gov: Id. Nr. NCT01139489, at www.trialregister.nl: Id.
nr. NTR1861.
Keywords: Antibiotics, Antibiotic duration, Biomarker, Critical illness, C-reactive protein, Defined daily dosage,
Intensive care unit, Procalcitonin, Sepsis, Septic shock
Background
Resistance to antimicrobial drugs is an increasing threat
to public health. Each year, about 25.000 people die in
the EU from an infection with multidrug-resistant bac-
teria. In the EU infections due to such bacteria result in
extra healthcare costs of over 1.5 billion Euros each year
[1]. The reasons for the increase in antimicrobial resist-
ance are complex, but it has become evident that un-
necessary prolonged use of broad-spectrum antibiotics is
linked to the emergence and selection of resistant
bacteria, and longer hospitalization [1]. The Netherlands
have long been known for its prudent use of antibiotics
and its subsequent low number of multi-resistant organ-
isms. However, in the Netherlands in recent years a
gradual increase in multi-resistant organisms has been
found, mainly located in nursing homes and intensive
care units (ICU’s).
In general, the use of different classes of antibiotics has
grown steadily in hospitals [2]. In 2000, a survey in Dutch
hospitals showed that the overall use of systemic antibi-
otics was 43 Defined Daily Dose (DDD)/100 patient-days.
In 2009 the use of systemic antibiotics had already
increased to 70.9 DDD/100 patient-days [3]. In the ICU’s
of these hospitals the average use was twice as high
(132 DDD/100 patient-days in 2006) [4].
Delayed antibiotic therapy is associated with a worse
outcome for patients presenting with a severe acute
infection. Each hour of delay in the administration of
antibiotic therapy in the first six hours is associated with
an average decrease in survival of more than 7% [5]. It is
therefore advised to start antibiotics as soon as possible
whenever sepsis is considered. Although rapid and ad-
equate antibiotic therapy is of great importance, it is ob-
vious that aggressive strategies can easily lead to a high
consumption of broad-spectrum antimicrobial agents.
Unfortunately, no objective measures exists on how long
antibiotic therapy should be applied. To address the po-
tential overuse of antimicrobial agents, trials have used
biomarkers to provide additional objective information
about the extent of systemic inflammation and to optimise
the duration of antibiotic therapy. Conventional clinical
signs such as fever, leukocytosis or increased C-reactive
protein (CRP), have proven to be neither specific nor sen-
sitive enough for the diagnosis or treatment of infections
in ICU patients.
Over the past two decades procalcitonin (PCT) has
been extensively studied as a serum marker of systemic
infection and sepsis. Being the precursor of the active
hormone calcitonin, PCT is a 116 amino-acid peptide
that can be elevated by several orders of magnitude in
systemic inflammation accompanying sepsis [6,7]. It has
been shown that after trauma or surgery the levels of
PCT usually stay below 1 ng/ml [8]. On the other hand,
PCT levels that are clearly above 1 ng/ml are often asso-
ciated with severe bacterial infections that manifest
themselves as sepsis and septic shock [6-10].
Previous studies have shown that PCT-guided therapy
is not only beneficial for respiratory tract infections
[11-14], but also provide useful guidance for antimicro-
bial treatment in critically ill patients in the ICU who
are treated for suspected bacterial infection [15-19]. The
large French multicenter PRORATA study demonstrated
that patients in the PCT group had significantly more
antibiotic free days than patients in the control (usual
care) group (14.3 days [SD 9.1] vs. 11.6 days [SD 8.2])
[17]. Mortality in the PCT group was non-inferior to
that in the control group. Criticism focused on potential
treatment bias, unclear adherence to guidelines in the
control group, the sample size (630 randomized patients
may be underpowered), and especially the 10% non-
inferiority margin. The 10% inferiority margin ought to
have been a relative measure. However, the PRORATA-
study was powered upon a 10% absolute difference in
mortality. Such a difference is generally considered un-
acceptable. Therefore, safety issues remain and it is also
not clear whether such a PCT-guided strategy is effective
in a setting with relatively low antibiotic consumption
and low resistance such as the Netherlands. PCT-guided
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antibiotic therapy might be beneficial to patients but also
to the society at large, because it may lead to lower costs,
fewer side effects originating from antibiotic usage and, in
time, potentially a decrease in multidrug-resistance. Thus,
we designed a large multicenter Dutch PCT-guidance trial
to address all of these issues, in particular the optimisation
of antibiotic therapy duration in critically ill patients on
the ICU, currently solely based on empirical guidelines.
Methods and design
Study aim
The objective of this trial is to establish whether the
PCT-guided strategy is superior to standard of care
based on existing experience, expertise and implemented
guidelines. The primary efficacy endpoint is that PCT-
guided strategy is superior in terms of antibiotic use,
expressed as the Defined Daily Dosage (DDD), and
duration of antibiotic therapy expressed in days of ther-
apy. As this trial is designed to shorten antibiotics safely,
the primary safety endpoint will be overall mortality
measured at 28 days and at 1 year.
Secondary endpoints are reinfection rate, length of
stay in the ICU and cost effectiveness.
Study design and setting
This is a nationwide multicenter prospective, randomised,
controlled, open intervention trial performed in 16 Dutch
surgical and medical ICU’s.
The Ethics Committee of the VU University Medical
Center Amsterdam, Netherlands, approved the study
protocol which is in full compliance with the Helsinki
declaration. The study is coordinated by a steering
committee (the authors), consisting of intensivists from
participating ICU’s, who all contributed to the design
and execution of this trial. Furthermore, a statistician, an
epidemiologist and a pharmacist support the steering
committee.
The trial is supervised by an independent safety moni-
toring board that is not involved in the design and
conduct of the trial, or in the recruitment of patients.
The board consists of a pulmonologist, an intensivist
and a statistician.
Stratification, randomisation and blinding
Patients will be stratified by diagnosis and centre. Strati-
fication will be performed according to the diagnosis of
sepsis, severe sepsis and septic shock. Allocation of
patients to either treatment group is concealed by using
a centralised randomisation procedure with a computer
generated list produced by an independent research
organisation, the Julius Center for Human Research,
Utrecht, the Netherlands.
Patients
Included will be patients with an age >18 years, and for
whom antibiotics were initiated for an assumed or
proven infection on admission or during ICU admission.
Current guidelines, like the Surviving Sepsis guidelines,
advocate swift initiation of antibiotics whenever infec-
tion/sepsis is considered [5]. This study will not interfere
with this decision of the physician to start antibiotics.
The study, therefore, is the ultimate combination of
early-goal-directed therapy and reduction of antibiotic
duration. Patients can be included within 24 hours after
receiving their first dose of antibiotics. Informed consent
has to be obtained in writing from the patient or his or
her legal representatives prior to inclusion.
Exclusion criteria are: (1) the inability to acquire a writ-
ten informed consent, or (2) when prolonged antibiotic
therapy is indicated (>3 weeks, e.g. endocarditis, cerebral/
hepatic abscess), (3) patients with severe infections due to
viruses, parasites or tuberculosis, (4) patients entering the
ICU for merely short-term post-operative observation, (5)
patients with an estimated length of stay less than 24 hrs,
(6) patients suffering from cystic fibrosis, (7) severely
immunocompromised patients such as patients with HIV
and a CD4 count of less than 200 cells/mm, neutropenic
patients (<500 neutrophils/mL), (8) patients with solid
organ transplantation, or (9) moribund patients.
The use of corticosteroids does not interfere with PCT
measurements, while effects on CRP levels have been
demonstrated [20]. Since the purpose of this study is to
demonstrate the efficacy and safety of PCT-guided
therapy in a real-life setting patients on corticosteroid
therapy will not be excluded from the study. Use of
systemic corticosteroids will be monitored and recorded
throughout the trial.
Treatment and intervention
The decision to start antibiotic treatment will in no way
be affected by the trial. In all patients antibiotics will be
started based on a clinical suspicion of infection or
microbiological evidence of infection. This decision is
fully at the discretion of the treating intensivist. Once
antibiotics are administered for newly suspected or
proven bacterial infection, patients or their legal represen-
tatives will be asked for informed consent. If informed
consent is obtained, the patient will be randomised to ei-
ther the standard therapy arm (control group) or the PCT
arm (intervention group). Randomisation will be stratified
for diagnostic group and study centre. When a patient is
randomised for the control group, no PCT measurements
will be performed. Other laboratory tests for infection
such as CRP are allowed. When a patient is randomised
for the PCT group, PCT will be measured at base-line
called the T0-serum sample (T0: as close to initiation of
antibiotics as possible, at least within 24 hrs). On the
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following days the ICU team will be provided with daily
PCT values until ICU-discharge or until the third day after
all systemic antibiotics have been discontinued. Along
with daily PCT values a non-binding advice will be gener-
ated to consider stopping the prescribed antibiotics if
PCT has decreased to <20% of its peak value (relative
stopping threshold) or has reached a value of below
0.5 ng/ml (absolute stopping threshold). PCT levels will
not be used to initiate antibiotic therapy. In case of two
consecutive PCT levels below 0.5 ng/ml a stopping advice
will be generated.
As for the control group, the physician will receive
routine daily laboratory values as requested and no add-
itional advice. Thus, treatment for both patient groups
will be based on existing experience, expertise and local
protocols, however, in the intervention group doctors
are additionally provided with daily PCT levels, and a
non-binding advice on continuation or discontinuation
of antibiotic therapy by email, electronic patient data
management system feedback, or research nurses. In
both groups daily multidisciplinary reviewing will be
performed on antibiotic therapy and duration, based on
the clinical course, microbiological results and treatment
guidelines. If doctors do not adhere to the stopping
rules, reasons for non-adherence will be recorded.
Data collection and management
Data management will be performed by the investigators
or research nurses of the participating ICU. The investi-
gators must ensure that the patient’s anonymity is
maintained. The subjects will be identified by a trial
identification number. The list containing the subjects
name and allocation numbers are kept in strict confi-
dence by the principal investigator. The database used
for electronic data transfer of any clinical research file
(CRF) or subject related data will be protected by a
password. Data base integrity and data safety as well as
privacy are warranted by the contracted research
organisation, the Julius Center for Human Research,
Utrecht, the Netherlands.
Procalcitonin assays
PCT will be measured with various validated assays: the
automated Kryptor platform (Thermo Fisher Scientific,
Hennigsdorf, Germany), the Roche Elecsys Thermo Fisher
Scientific PCT assay, the Siemens Centaur Thermo Fisher
Scientific PCT assay or using BioMerieux’s Vidas Thermo
Fisher Scientific PCT assay. The Thermo Fisher Scientific
Kryptor sensitive PCT will be applied on this platform using
Time Resolved Amplified Cryptate Emission (TRACE)
technology and is based on a polyclonal antibody against cal-
citonin and a monoclonal antibody against katacalcin, which
binds to the calcitonin and katacalcin sequence of the calci-
tonin pro-hormone. The test is considered a homogeneous
immunoassay (sandwich principle) and is validated on serum
and plasma (EDTA and heparin) matrix. The direct measur-
ing range of the assay is from 0.02-50 ng/ml, with automated
dilution extending the upper range to 1000 ng/ml. The
Functional Assay Sensitivity (FAS) is 0.06 ng/ml.
The Roche Elecsys Thermo Fisher Scientific PCT assay
also uses an immunoassay based on a sandwich principle
based on a polyclonal antibody against calcitonin and a
monoclonal antibody against katacalcin, which binds to the
calcitonin and katacalcin sequence of the calcitonin
prohormone. The direct measuring range of the assay is
from 0.02-100 ng/ml. The Functional Assay Sensitivity (FAS)
is 0.06 ng/ml. Procedure time of the assay is 18 minutes.
The assay is validated on serum and plasma (EDTA and
heparin) matrix.
The BioMerieux Vidas Thermo Fisher Scientific PCT
assay is an Enzyme-Linked Fluorescent Assay (ELFA)
involving a one-step immunoassay sandwich method
using a Solid Phase Receptacle (SPR). The system uses a
ready to use test strip into which a sample volume of
200 micro litres of serum or lithium heparin plasma is
pipetted. The direct measuring range is 0.05-200 ng/ml.
The FAS is determined to be 0.09 ng/ml.
Procedure time for all these assays is less than 30 minutes.
Each participating centre will have access to a Kryptor
machine, a suitable Vidas or Roche immunoanalyser to
expedite the determinations and its adjunctive advice.
Whenever results exceed the maximum measuring
range of any of the above described machines, manual
dilution will be used, in accordance with the manufac-
turer’s specifications to achieve the true quantified value
of a patient result. All patient results will be given in
two decimals for the entire measuring range.
Sample size and statistical analysis
Antibiotic duration is the main primary outcome of this
on-going study. The expected standard deviation (SD) of
antibiotic treatment, based on previous intervention
trials [15-20] will be 6 days in both groups. Assuming a
mean baseline antibiotic duration of 8 days, with a
significance α-level of 5% and a power of 90%, 757
patients are needed in both groups. Patients that are
discharged from the ICU before a stopping advice could
have been issued and who are still being treated with
antibiotics are considered “dropped out”. Assuming a
drop-out rate of 20%, we need to include 908 patients in
each group, so for the superiority margin in total 1816
patients will need to be included.
As the PCT intervention arm should be non-inferior,
in terms of safety (mortality), in comparison to the
standard treatment, the non-inferiority margin for PCT
guided antibiotic management regarding 28-day-mortal-
ity is set on 8%. Based on previous trials, like the
PRORATA-study [17], we assumed a 28% mortality rate
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in each group. With a one-sided significance α-level of
2.5% and a power of 90%, 714 patients are needed in
both groups. Again with a drop-out of 20%, 1714
patients will need to be included. With such a sample
size (and alpha 5% and beta of 20%) we would have been
able to detect a 15% relative increase in mortality. Such
conventional boundaries are very acceptable in most
trials investigating the efficacy of new drugs. Here, we
aim to do better, with an alpha of 2.5% and beta of 10%.
Losses to follow-up on both arms will be registered
including the reason for loss to follow-up. Furthermore,
the primary endpoint will be explored for association
with potential prognostic factors in a survival analysis.
The factors that will be considered are age, sex,
APACHE IV-score, SOFA-score and usage of corticoste-
roids or dialysis.
The primary analysis population will consist of all ran-
domized patients following the intention-to-treat principle.
For the primary analysis, losses to follow-up (in both arms)
will be included in the 28-day analysis of mortality and
antibiotic consumption. The primary analysis will be
repeated with the subset of patients who complied with the
stopping threshold, as so-called “per protocol analysis” of
mortality and antibiotic consumption on day 28.
Interim analysis
The first interim analysis was performed after enrolment of
750 patients. Preceding this analysis the non-inferiority
margin was set at 8% and a p-value of 0.0294 was used, cor-
responding with the performance of one interim-analysis in
accordance with the Pocock method [21]. The DSMB
examined the data and the trial would have been stopped
immediately if the above predefined margins were reached.
Furthermore, the DSMB reviewed the trial’s progress and
adverse events according to treatment assignment.
Duration
With the current inclusion rate of 50 patients per
month, the total duration time is estimated at 36 months




The additional prognostic value of PCT in some critic-
ally ill patients has repeatedly been demonstrated. Until
now six randomized controlled trials have been pub-
lished that addressed the effectiveness and safety of
PCT-guided strategy in antibiotic treatment of septic
patients in adult intensive care units (ICU’s) [15-19,22],
Several systemic reviews have been performed [23-28]
and even an individual patient data meta-analysis in
acute respiratory infections was published recently [14].
Thus, the question arises whether another study is
warranted. The six trials were done with either small
sample sizes or within highly selected populations
[15-20]. Hochreiter [16] and Schroeder [8] both included
patients after abdominal surgery. Svoboda et al. investi-
gated 72 patients after abdominal surgery or surgery for
major multiple trauma, using a semi-quantitative PCT
assay [19]. Stolz et al. included 101 patients with only
ventilator-associated-pneumonia [18]. Schuetz and col-
leagues have performed a individual patient data meta-
analysis in patients with an acute respiratory infection
[14]. This study combined 4550 patients with a suspicion
of respiratory infection of which 598 patients were
admitted to the ICU. Even in these severely ill patients
the median duration of antibiotic treatment was reduced
from 12 days to 8 days (P < 0.001). The two remaining
studies have been published with a heterogeneous
adult ICU population [15,17]. Remarkably, Nobre et al.
excluded 203 out of 282 patients [15]. Due to strict
exclusion criteria, this trial included only 79 patients.
Therefore, the PRORATA-study appears to be the only
study with a larger number of adult patients in a hetero-
geneous critically ill population [17]. This study was
designed as a both a start and stop study and comprised
predominantly non-surgical patients (10% were surgical).
Within the study a clear reduction of 2.7 days in anti-
biotic treatment duration was seen in the PCT arm.
However, concerns exist about mortality statistics, the
lack of power, and potential treatment bias. Further-
more, it is important to recognise that this study was
performed in France, with one of the highest baseline
antibiotic consumption rates in Europe. Therefore, it is
important to investigate, in particular in a country with
a relatively low antibiotic consumption, if PCT-guidance
will lead to reduction of antibiotic use.
More recently, the PASS study was published [22].
This study was not intended to reduce antibiotic
duration. The objective was to analyse whether PCT
guidance was able to detect an infectious deterioration
and could lead to improvement of the 28-day survival in
1200 ICU patients [22]. This trial did not show that a
PCT-guided algorithm lead to improved outcome. In
contrast, patients in the PCT arm had a longer LOS and
used more antibiotics than the patients in the control
arm.
SAPS-trial
The SAPS study was conceived to include a heteroge-
neous ICU patient population in a real life setting, focus-
ing only on the additional value of PCT in guiding
antibiotic treatment. The rather large sample-size (over
1800 patients) allows for adequate testing of both efficacy
(consumption of antibiotics) and safety (mortality, recur-
rent infections). This is a multicenter study (16 centres)
with an estimated high recruitment rate (5 patients/month
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in a 10-bed ICU). The anticipated antibiotics use in both
trial arms will be low compared to the studies from France
or the US. Patients on selective decontamination of the di-
gestive tract (SDD) will not be excluded. Another import-
ant aspect of the SAPS trial will be costs-analysis. So far
only one study gathered data on costs of the PCT-based
strategies in the ICU; however this study enclosed only 27
patients, who all underwent abdominal surgery [19].
When antibiotics are reduced by PCT-guided therapy,
economic aspects should certainly be considered, acknow-
ledging that PCT is more expensive than common labora-
tory biomarkers like CRP. As has been repeatedly noted
by authors critical of PCT as a sole indicator of sepsis,
PCT should be viewed together with other information,
including fever, leukocyte count and very importantly,
CRP. Irrespective of the relative merits of CRP and PCT,
the de facto situation is that most ICU’s regularly perform
the relatively inexpensive CRP-assay. This is also the case
in ICUs that participate in the SAPS-study. Thus, in the
PCT-arm of the SAPS-study, clinicians will inevitably
judge PCT and CRP levels in conjunction. It will thus be
of great interest if the PCT-assay that is currently consid-
erably more expensive than CRP, making up for its costs
in reducing antibiotic costs.
SAPS therefore not only aims to address issues of
effectiveness or safety, but also unanswered questions
regarding cost-effectiveness.
It should be stressed that when antibiotics are reduced by
a PCT-supported therapy, the safety of such an interven-
tion is paramount. Only without an increase in mortality
during a long-term follow-up for the PCT-guided group,
can this intervention prove itself to be acceptable. In the
aforementioned studies no statistically significant difference
in mortality was found between patients managed with
PCT-guided algorithms versus ‘standard of care’. However,
in the PRORATA-study the non-inferiority margin was set
on 10% (absolute increase), and within this margin no
statistical significant effect on mortality was noted. How-
ever, the 60-day mortality was 3.8% higher in the PCT-
guided group. With a 90% confidence interval, the lower
limit was 9.7%, approaching the preset 10% margin, which
led to some criticism [28]. The authors proclaimed, how-
ever, that this non-inferiority margin in a real life setting
was in accordance with international recommendations for
non-inferiority trials assessing antibiotic treatment for
severe community-acquired pneumonia or for assessment
of new antibacterials. However, an increase of mortality
from 5-10% [29] to 20% in community-acquired pneumo-
nia would not be considered acceptable. The SAPS-study
will set the non-inferiority margin at 8%. Theoretically, an
even lower margin will be favourable, however this would
require an unrealistic sample size with several thousands
of patients and thereby rendering such an investigation,
unfortunately, unenforceable.
Another aspect is optimisation of PCT cut-off values
that are applicable in the intensive care department.
There is still an on-going discussion about what cut-offs
should be used for PCT to optimise antibiotic therapy.
In SAPS we apply stopping rules similar to those used in
the PRORATA-trial. Although some may considerer the
PRORATA and SAPS stopping rules conservative, we
consider it prudent to carefully examine the clinical
value of this rule through trials, before considering new
rules. Finally, even if the primary endpoints of this trial
are not achieved, this trial will still be of great value, as
it will provide important insights in the optimisation of
antibiotic therapy in Dutch ICUs.
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